Does anyone have any link to studies on the comparative effectiveness of the PCSK9 inhibitors such as Evolocumab versus the HMG Co-A Reductase Inhibitors (Statins) in the treatment of dyslipidemia? Including comparative effect on mortality .
Hi,Chukwuma ,,I totally agreed with Andrei's answer. Everything almost told. Probably three is no study to compare head to head between statin and Pcsk9 inhibitor because nobody can be deprived the proven benifits of statin in reducing cardiovascular mortality of statin. Meta-analysis of various trials showed that three are suggestion that pcsk9inhibitor has cardiovascular and all cause mortality benefit. It is very effective in reducing LDL cholesterol in alone and also in combination with statin. It could be very effective drug in patient of familial hypercholesterolemia where statin alone may not very effective.. Thanks
The studies on Repatha are too short to have an effect on mortality. Indeed, if some of the non-Repatha people in the trials quit smoking cigarettes, their atherothrombotic disease (ATD) events will be delayed by about 12 years, so no mortality differences would be evident. That said, if one reduces ATD events, mortality rates should fall.
Recent results show that statins can upregulate PCSK9. We detect the free PCSK9 in patients during Evolocumab therapy and can see an increased PCSK9 protein level in patients under statin/evolocumab co treatment compared with evolocumab single therapy.
- Badges
- Science topic